Aptar Pharma Returns to DDL 2026 as Platinum Sponsor
Aptar Pharma is pleased to return to DDL 2026 as a Platinum Sponsor, alongside Nanopharm, an Aptar Pharma company. Taking place December 9-11, 2026, at the EICC in Edinburgh, the DDL conference offers the opportunity to explore new research in nasal and pulmonary drug delivery, formulation, next-generation propellants and aerosol performance.
Aptar Pharma will be at Booth 150 and Nanopharm at Aptar Pharma Services' Booth 194 throughout the three-day conference. The team from PULMOTREE, recently acquired by Aptar Pharma, will also be on hand to discuss the Kolibri™ Non-Propellant Liquid Inhaler platform and its potential to support next-generation inhaled therapies, including biologics.
Podium lectures at DDL
Aptar Pharma will deliver two podium lectures at DDL this year:
- Session 5: Propellants, Planet & Patients: Clinical Needs and Advocacy - Thursday, 10 December
Next-Generation Propellants in pMDIs: Why Valve Design Becomes a Critical Performance Driver will be presented by Lucas Silva, Director Business Development & Technology Pulmonary, Aptar Pharma (16:50 GMT).
- Session 6: Site-specific Aerosol Delivery - Friday, 11 December
Towards Standardised Compendial Testing of Nasal Products: Multi-Laboratory Evaluation of the Kiel Nasal Inlet for Assessment of the <10 µm Fraction will be presented by Gonçalo Farias, Analytical and Innovation Hub Manager, Aptar Pharma (12:05 GMT).
Four scientific posters
Alongside the podium lectures, experts from Aptar Pharma and Nanopharm will also present posters on formulation development, nasal and pulmonary drug delivery, next-generation pMDIs and analytical science.
The scientific posters will include:
- Development of Peptide Nasal Powders by Moisture-Activated Dry Granulation - Sana Hosseini, Aptar Pharma
- Predictive Modelling of Droplet and Particle Size Distributions for Spray-Dried Intranasal Powders - Sana Hosseini, Aptar Pharma
- Application of Design of Experiments for the Development of a Semi-Automated Method for pMDIs Using Next-Generation Propellants - Gregoire Deraime, Aptar Pharma
- Development of Oligonucleotide Powders for Intranasal and Pulmonary Delivery - Antonia Zapata del Baño, Nanopharm
Delegates attending DDL 2026 can book a meeting with Aptar Pharma experts to discuss your nasal or pulmonary drug development challenges and find out how Aptar Pharma can support your next project. Contact Us